2025 年 12 月 24 日，武 汉大学 闫卫 教授团队在 Nature 子刊 Nature Aging 上发表了题为： Cancer-cell-secreted DDAH1 induces TGF-β1/Smad3 signaling pathway to promote fibrosis and aging in lung 的研究论文。 该研究表明，癌细胞分泌的 DDAH1 蛋白通过诱导 TGF-β1/Smad3 信号通路，促进肺纤维化和肺衰老，而抑制 DDAH1 可有效减轻肺纤维化并延缓肺衰老。 肺衰老 （ Lung aging ） 是一系列多因素引发的分子改变，最终导致肺功能逐渐恶化且更易罹患癌症。肿瘤细胞部分通过细胞外囊泡 （ extracellular vesicle， EV ） 与宿主器官进行信息交流，然而，在癌症背景下肺衰老的机制驱动因素及其影响，目前尚不明确。 撰文丨王聪 编辑丨王多鱼 排版丨水成文 总的来说，该研究揭示，肿瘤源性 DDAH1 蛋白通过促进瓜氨酸积累加速肺衰老进程，为通过抑制衰老肺成纤维细胞来治疗和诊断肿瘤提供了新思路。 论文链接 ： https://www.nature ...

Core Insights - Guangdong Hengrui Medicine Co., Ltd. has initiated a Phase I clinical trial for HRS-9813, a drug aimed at treating pulmonary fibrosis, with the trial registered under CTR20254413 and publicly announced on November 6, 2025 [1] Group 1: Clinical Trial Details - The primary objective of the trial is to evaluate the pharmacokinetic interactions of HRS-9813 capsules with pirfenidone and nintedanib in healthy subjects [1] - Secondary objectives include assessing the safety and tolerability of the drugs when used alone and in combination, as well as exploring the metabolic characteristics of HRS-9813 in healthy subjects [1] - The trial is currently ongoing with a target enrollment of 20 participants, although recruitment has not yet started [2] Group 2: Drug Information - HRS-9813 is a chemical drug indicated for pulmonary fibrosis, a condition characterized by lung tissue damage leading to scarring, with symptoms including dry cough and progressive shortness of breath [1] - High-resolution CT scans can assist in the diagnosis of pulmonary fibrosis [1]